Treat severe cases of infection at COV with XAV-19

Project Information

BRIGHT

Grant agreement ID: 962036

DOI

10.3030/962036

Project closed

EC signature date 27 July 2020

Start date 1 August 2020

End date 31 December 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost

€ 3 127 625,00

EU contribution

€ 2 162 650,00

Coordinated by

XENOTHERA
France

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Other (1)

Anti-SARS-CoV-2 swine glyco-humanized polyclonal antibody XAV-19 retains neutralizing activity against SARS-CoV-2 B.1.1.529 (Omicron)

Author(s): Bernard Vanhove, Stéphane Marot, Gwénaëlle Evanno, Isabelle Malet, Gaëtane Rouvray, Françoise Shneiker, Edwige Mevel, Carine Ciron, Juliette Rousse, Pierre-Joseph Royer, Elsa Lheriteau, François Raffi, Odile Duvaux, Anne-Geneviève Marcelin, Vincent Calvez
Published in: bioRxiv, 2022
Publisher: bioRxiv
DOI: 10.1101/2022.01.26.477856

Peer reviewed articles (4)

Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial

Author(s): Benjamin Gaborit, Bernard Vanhove, Marie-Anne Vibet, Aurélie Le Thuaut, Karine Lacombe, Vincent Dubee, Florence Ader, Virginie Ferre, Eric Vicaut, Jéremie Orain, Morgane Le Bras, Anne Omnes, Laetitia Berly, Alexandra Jobert, Pascale Morineau-Le Houssine, Karine Botturi, Régis Josien, Laurent Flet, Nicolas Degauque, Sophie Brouard, Odile Duvaux, Alexandra Poinas, François Raffi
Published in: Trials, Issue 22/1, 2021, ISSN 1745-6215
Publisher: BioMed Central
DOI: 10.1186/s13063-021-05132-9

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants

Author(s): Vanhove B, Marot S, So RT, Gaborti B, Evanno G, Malet I, Lafrogne G, Mevel E, Ciron C, Royer PJ, Lheriteau E, Raffi F, Bruzzone R, Mok CKP, Duvaux O, Marcelin AG, Calver V
Published in: Frontiers in Immunology, Issue Vol 12, 2021, ISSN 1664-3224
Publisher: Landos Biopharma Inc
DOI: 10.3389/fimmu.2021.761250

Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study

Author(s): Benjamin Gaborit, Eric Dailly, Bernard Vanhove, Régis Josien, Karine Lacombe, Vincent Dubee, Virginie Ferre, Sophie Brouard, Florence Ader, Marie-Anne Vibet, Aurélie Le Thuaut, Richard Danger, Laurent Flet, Anne Omnes, Laetitia Berly, Anne Chiffoleau, Alexandra Jobert, Odile Duvaux, François Raffi
Published in: Antimicrobial Agents and Chemotherapy, Issue 65/9, 2021, ISSN 0066-4804
Publisher: American Society for Microbiology
DOI: 10.1128/aac.01237-21

High neutralizing potency of swine glyco‐humanized polyclonal antibodies against SARS‐CoV‐2

Author(s): Bernard Vanhove, Odile Duvaux, Juliette Rousse, Pierre‐Joseph Royer, Gwénaëlle Evanno, Carine Ciron, Elsa Lheriteau, Laurent Vacher, Nadine Gervois, Romain Oger, Yannick Jacques, Sophie Conchon, Apolline Salama, Roberto Duchi, Irina Lagutina, Andrea Perota, Philippe Delahaut, Matthieu Ledure, Melody Paulus, Ray T. So, Chris Ka‐Pun Mok, Roberto Bruzzone, Marc Bouillet, Sophie Brouard, Emanuel
Published in: European Journal of Immunology, Issue 51/6, 2021, Page(s) 1412-1422, ISSN 0014-2980
Publisher: John Wiley & Sons Ltd.
DOI: 10.1002/eji.202049072

Intellectual Property Rights

Patent (1)

COMPOSITION WITH REDUCED IMMUNOGENICITY

Application/Publication number: 20 15073892
Date: 2015-10-15
Applicant(s): XENOTHERA